Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases

doi:10.3748/wjg.v21.i24.7584

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8072)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

586

WORD

182

HTML

4047

Tables (1-2)

170

Sum=4985

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1165

Download

1906

Sum=3071

Jun 28, 2015 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (85)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Jun 28, 2015; 21(24): 7584-7588
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7584

Table 1 Clinical characteristics of the patients in the series

Age/Gender	Disease/Disease duration	Anti-TNF drug	Dose mg/kg/number infusions/injections	Concomitant drugs	Symptoms	Transaminase levels (ALT/AST - x ULN)	Autoantibodies/ Immunoglobulins	Histology	AIH scorePost-therapy	Steroid response	Maintenance therapy	Outcome
1 - 36F	Distal UC/7 yr	IFX	5 mg/kg/5	Mesalamine	Yes	14/9	Anti-dsDNA, ANA, High IgG	Interface hepatitis	20	Yes	Mesalamine 3 g/d PO	Reversibility
2 - 45F	RA/10 yr	ADA	40 mg EOW/11	MTX NSAIDs	No	4.5/3	ANA, High IgG	Severe interface hepatitis	19	Yes	AZA 50 mg, ETC, Prednisolone 7.5 mg	Reversibility
3 - 34F	Distal UC/2 yr	IFX	5 mg/kg/8	Mesalamine	Yes	4.5/3	ANA, High IgG	Interface hepatitis	20	Yes	Mesalamine 3 g/d PO	Reversibility
4 - 35M	Extensive UC/2 yr	IFX	5 mg/kg/8	Mesalamine	No	13/7	ANA, High IgG	Interface hepatitis/marginal proliferation of bile ducts	20	Yes	Mesalamine 3 g/d PO	Controlled on therapy
4 - 35M	Extensive UC/2 yr	IFX	5 mg/kg/8	Mesalamine	No	13/7	ANA, High IgG	Interface hepatitis/marginal proliferation of bile ducts	20	Yes	AZA 2.5 mg/kg per day	Controlled on therapy
5 - 43M	AS/30 yr	IFX	5 mg/kg/5	-	No	25/15	High IgG	Interface hepatitis/cirrhosis	20	Yes	AZA 50 mg, Prednisolone 10 mg	Controlled on therapy
6 - 66F	Ileal CD/11 yr	IFX	5 mg/kg/13	Mesalamine, AZA	No	2/5	ANA	Chronic lymphoplasmocytic infiltrate	19	Yes	IFX 5 mg/kg AZA 2.5 mg/kg per day	Reversibility
7 - 37M	Ileal CD/2 yr	IFX	5 mg/kg/12	Mesalamine (suspended INH 2 mo prior to IFX)	No	4/2	ANA, High IgG	Interface hepatitis	20	Yes	Mesalamine 3 g/d PO	Reversibility
8 - 69F	Ileal CD/32 yr	IFX	5 mg/kg/4	Mesalamine	No	10/5	ANA	Interface hepatitis	19	Yes	Mesalamine 3 g/d PO	Reversibility

AS: Ankylosing spondylitis; PsA: Psoriatic arthritis; ULN: Upper limit of normal; UC: Ulcerative colitis; RA: Rheumatoid arthritis; CD: Crohn’s disease; PPP: Palmoplantar pustular psoriasis; PsO: Psoriasis; IFX: Infliximab; ADA: Adalimumab; ETC: Etanercept; AZA: Azathioprine; MTX: Methotrexate; INH: Isoniazid; EOW: Every other week; dsDNA: Double strand DNA; ASMA: Anti-smooth muscle antibodies; AMA: Anti-mitochondrial antibodies.

Citation: Rodrigues S, Lopes S, Magro F, Cardoso H, Horta e Vale AM, Marques M, Mariz E, Bernardes M, Lopes J, Carneiro F, Macedo G. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. World J Gastroenterol 2015; 21(24): 7584-7588
URL: https://www.wjgnet.com/1007-9327/full/v21/i24/7584.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i24.7584